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I. Introduction
On December 27, 2002 a company called Clonaid announced the birth of a cloned human.1 Clonaid an-
nounced the birth of a second child on January 4, 2003.2 Clonaid was founded by the leader of a religious
sect known as the Raelians. This individual, a French expatriate named Claude Vorilhon, also goes by the
name Rael.3 He and his group are probably the most vociferous and well-known advocates of applying
cloning technology to human beings.
What motivates the desire to make human clones? Vorilhon, reportedly born out of wedlock, was abandoned
by his parents at an early age.4 While cloning may be an attractive option for those in similar situations,
aversion to the so-called traditional concept of parentage, where one is reared by biological parents, is not the
only reason why people might be interested in cloning as a potential reproductive means. Other motivations
include the desire to see a clone of oneself grow to adulthood,5 the lack of any other reproductive option,6
and the need to compensate for the loss of a loved one.7
∗Submitted to Professor Peter Barton Hutt in partial fulﬁllment of the requirements for Food & Drug Law, 2003 Winter
Term, Harvard Law School.
1See The White House Bulletin, CNN Live Today, 10:00, December 27, 2002, Transcript # 122702CN.v75.
2See London Free Press, January 5, 2003, at A8.
3See id.
4See Rick Ross, The True Story of “little Claudy” Vorilhon, now known as “His Holiness Rael” (March 2003), at
http://www.rickross.com/reference/raelians/raelians77.html.
5See Richard Dawkins, What’s Wrong With Cloning?, in Clones and Clones 54-66 (Martha C. Nussbaum and Cass R.
Sunstein, eds., 1998).
6See The First Human Cloning Company, at http://www.clonaid.com/english/pages/services.html (last visited May 14,
2003).
7Id.
1Vorilhon and the Raelians, on the other hand, have leached upon a motivation that has tantalized human
beings since the dawn of civilization – the desire for immortality.8 In the aftermath of the recent cloning de-
bacle that witnessed the announcement of cloned children and subsequent months of hemming and hawing by
the Clonaid spokespeople, the pseudo-religious branch of Vorilhon’s activities under the guise of the Raelian
religion appears to have backed away from an overt connection to cloning. If the Raelian organizational
website is to be used as an indicator of the group’s focus, cloning is no longer the central emphasis of this
religion, at least for the moment.9 The website information conveys the belief that aliens were originally
responsible for life on Earth via DNA seeding.10 The website also goes so far as to assert that, in a Raelian
utopia, biotechnology will be used for the betterment of the human condition, but no speciﬁc mention of
cloning is made within the pages.11
At the same time, it would seem that a hot-button issue such as human cloning is too attractive of a potential
publicity vehicle to abandon altogether, especially for such an attention-hungry organization as the Raelians
and, perhaps more precisely, a self-aggrandizing machinator recently characterized in the mainstream scien-
tiﬁc community as “charlatans.”12 Thus, it comes as no surprise that, despite the present dissociation from
the primary website text of language related to human cloning, there are still mentions of cloning, such as an
advertisement for a book entitled, “Yes to Human Cloning.”13 This link from the Raelian homepage leads
to a shopping page.14 The book synopsis reveals the promise of eternal life through cloning and memory
transfer. The Raelian group still maintains a vested interest in the exploitative power of human cloning, if
8See Raelian Leader Says Cloning First Step to Immortality, CNN.com, December 28, 2002; Probing Asian Clone Link,
CBSNews.com, January 4, 2003, at http://www.cbsnews.com/stories/2003/01/03/tech/main535105.shtml (last visited May
14, 2003) (quoting Vorilhon as saying, “I think it’s a big step for human beings in the future. It will bring us eternal life. That’s
the best thing that can happen to humanity. We can not only cure all diseases but also it will give us eternal life”).
9See The Raelian Revolution, at http://www.rael.org/english/index.html (last visited May 14, 2003).
10See id.
11See id.
12See Gretchen Vogel, Misguided Chromosomes Foil Primate Cloning, 300 Science 226, 227 (2003) (quoting Professor Gerald
Schatten as saying, “This reinforces the fact that the charlatans who claim to have cloned humans have never understood enough
cell or developmental biology.”).
13See The Raelian Revolution, at http://www.rael.org/english/index.html (last visited May 14, 2003).
14See id.
2not so much in the actual beneﬁts.
A brief visit to the website of Clonaid, another one of Verhilon’s endeavors, veriﬁes this conclusion. Here,
the company bills itself as “The First Human Cloning Company.”15 The company has been described as
the “scientiﬁc arm” of the Raelians.16 Among the services oﬀered for sale are Insuraclone, Ovulaid, and
Clonapet. Insuraclone oﬀers to preserve a client’s cells in a cryogenic state, the idea being that, in the
event of future advances in biotechnology, healthy cells could be used to address various medical problems.
Ovulaid targets infertile women seeking to purchase eggs for the purpose of conceiving a child. The precise
mechanism of conception is not entirely clear from the website’s description. On the one hand, one would
think that Clonaid would be trying to sell the ability to make one’s own clone. A reading of the text under
Ovulaid, however, gives one the impression that the point here is to try to sell the clone of a diﬀerent person.
The product description reads that customers will have the option of “choosing their future babies from a
catalog showing the pictures of the donor egg women...”17 One cannot help but wonder whether Clonaid
is purposefully confusing the distinction between an egg donor and a donor of genetic material, since, under
the current understanding of cloning technology, these are two separate categories. Of course, for a company
integrally associated with a cult of ﬂying saucers and little extraterrestrial founder beings, it is not diﬃcult
to imagine a fast and loose treatment of scientiﬁc understandings.
What makes the Raelians and more particularly Clonaid alarming, however, is not the tendency to turn away
from science fact and embrace science ﬁction when convenient. Rather, the cause for elevated attention arises
from the potential for this group to undertake genuine scientiﬁc endeavors. The technology required to un-
dertake cloning attempts, while specialized and expensive, is not inaccessible.18 A brief examination of
15See The First Human Cloning Company, at http://www.clonaid.com/english/pages/home.html (last visited May 14, 2003).
16See Press Release, Cult’s human ‘cloning machine’ goes on display at the Science Museum (Jan. 22, 2003), available at
http://www.sciencemuseum.org.uk/corporate commercial/press/ShowPressRelease.asp?Show=166 (last visited May 14, 2003).
17See The First Human Cloning Company, at http://www.clonaid.com/english/pages/services.html (last visited May 14,
2003).
18For instance, one can go onto the Internet and ﬁnd lists of vendors for the most delicate and expen-
sive instrument required, the microinjector apparatus. See ISC Buyers’ Guide – Microinjection Apparatus, at
3the Clonaid website reveals that the company has at least a partial complement of the equipment needed
to carry out cloning attempts.19 Furthermore, several species of mammals have already been successfully
cloned. Cloning has been achieved in sheep, mice, cows, and other mammals. However, these attempts have
typically experienced failure rates of 97%.20 The unsuccessful attempts result in death during pregnancy
and even at birth, accompanied by physical abnormalities.21 If for no other reason than safety and the need
to prevent biological mishaps, any attempts to clone humans must now be stopped.
At the same time, it would be a fruitless and wasteful expenditure of resources to impose a ban on the
technology that has made human cloning almost feasible. In examining the justiﬁcations for this statement,
this paper will trace the history of advances in cloning technology and the motivations for making these
advances. For the most part, human cloning was not an end, or even a consideration, for early researchers
who made the key discoveries; rather, the focus was upon cloning animals for commercial or scientiﬁc
purposes. As a result, this research was not heavily scrutinized by the public and the regulatory community
until relatively late in the discovery process.
II. The History of Cloning Technology
A. From Frog Eggs to Farm Animals
The beginnings of cloning research trace back to the ﬁrst studies in embryology, when scientists studied frog
http://www.iscpubs.com/bg/us/prod/prod1939.html (last visited May 14, 2003)
19See The First Human Cloning Company, at http://www.clonaid.com/english/pages/products.html (last visited May 14,
2003); Promotional Video, id. at http://www.clonaid.com/common ressources/video/promo.ram (last visited May 14, 2003).
20See Anne McLaren, Cloning: Pathways to a Pluripotent Future, 288 Science 1775, 1779 (2000).
21Id.
4eggs to determine developmental processes. The reasons for using amphibian eggs instead of mammalian ones
were eminently practical. A frog’s egg measures approximately 2 millimeters in diameter, which, although
small, is nonetheless visible to the naked eye.22 On the other hand, a human egg is considerably smaller – at
100 micrometers, measuring approximately 5-10% of the diameter of the frog egg.23 The early stages of frog
development take place outside of the parents’ bodies. This made it possible for the developmental cycle to
be observed under laboratory conditions, with a microscope. A further advantage of studying frog was that
they produce an abundant number of eggs. One frog produces up to thousands of eggs at a time.24 For the
early scientists studying embryology, studying frog development was simply the only practical choice.
In 1938, Hans Spemann proposed a cloning experiment.25 Spemann, who had performed several notable
experiments with salamander embryos, had become fascinated with the potential of taking a nucleus from a
developed organism and transplanting it into an egg cell to see whether a normal embryo would develop.26
During the course of his career, Spemann was the ﬁrst person to demonstrate deﬁnitively that an organism
at the two-celled stage could be divided into two single-celled entities, and that each of those cells would
develop into an individual organism.27 The method by which Spemann accomplished this was nothing short
of ingenious. Like many scientiﬁc breakthroughs, Spemann’s methodology was refreshingly elegant. Spemann
used a very ﬁne thread of hair and, under a microscope, wrapped the thread around a salamander embryo
that was at the two-cell stage. The cells split into two individual cells, and each of those cells developed
into a viable salamander. Spemann, however, did not ﬁgure out an eﬀective way to transfer a nucleus from
22See “Evolution of Cells,” Biology 255, Miami University, at http://www.bio.miami.edu/tom/bil255/bil255goods/
01 cells.html (updated Aug. 26, 2002).
23See Sizes of Things, Biological Sciences 101, University of Nebraska, at http://niko.unl.edu/bs101/notes/sizes.
html (last visited May 14, 2003).
24See Gina Kolata, Clone: The Road to Dolly, and the Path Ahead 44 (1998).
25See McLaren, supra note 20, at 1777.
26See id.
27See Kolata, supra note 24, at.
5one cell into an egg cell. With respect to cloning, his historical role was to propose the basic idea. Other
scientists, in Spemann’s tradition, devised clever ways to carry out his conceptual imaginings.
The ﬁrst cloning experiments in frogs were performed in 1950 by Robert Briggs and Thomas J. King.28
The types of cells used were not from fully grown frogs, but rather blastula cells. These blastulas contained
approximately 10,000 cells overall, and while they were not as far along in development as the adult frog,
diﬀerentiation of the cells had already begun.29 In other words, the embryo at this point had already
advanced to the stage such that each individual cell could not, if separated from the rest of the embryo, give
rise to another organism.
Conceptually, the frog embryo experiment was straightforward. The nucleus of an unfertilized egg cell was
removed using a glass pipette having a much smaller diameter than that of the egg cell. Next, the nucleus
of a blastocyst cell was transferred into the egg. The overall blueprint followed the plan that Spemann had
laid out some dozen years earlier. However, Briggs and King still had to contend with the major obstacle
confronting Spemann, that is, how to remove from a cell a nucleus, without destroying that nucleus.30
The techniques employed by the ﬁrst experimenters in retrieving the nucleus which contained the full com-
plement of genetic information for the clone are quite similar to the ones used by modern day researchers.
The underlying idea is that the nucleus lies within the cell and needs to be taken out of the cell. What
Briggs and King did was to take a glass pipette with a very small diameter, smaller than that of the blastula
28See id. at 63.
29See id.
30See McLaren, supra note 20, at 1778.
6cell.31 Next, that pipette was used to suction up the cell, akin to how one would use a straw to suction up a
small ice cube. The vacuum pressure exerted upon the wall of the cell caused the cell membrane, the outside
layer of the cell, to burst open. At this point, the pipette was used to collect the cell nucleus, located in
its own compartmentalized unit.32 Of course, for the pipette to do this, its diameter was necessarily wider
than that of the nucleus. By using a pipette with these speciﬁcations – a diameter greater than that of the
nucleus but less than that of the cell membrane – Briggs and King were able to do what Spemann could
only conceptualize. Since then, scientists have been able to retrieve the nucleii of various types of cells for
cloning experiments.
Those early frog embryo experiments, using nucleii obtained from early-stage blastula cells, ultimately proved
successful. Of the 197 blastula nuclei transferred to frog eggs, 27 developed into tadpoles.33 However, the
true eﬃcacy of this technique in cloning fully grown frogs had yet to be proven. Blastula cells, though no
longer totipotent stem cells,34 are nonetheless found considerably earlier in development than are the cells
from a fully grown adult organism. The research of Briggs and King, although cause for optimism, was still
only the beginning of attempts to clone organism from fully diﬀerentiated adult cells.
This message became all the more clear when researchers following up on the work encountered diﬃculties
when attempting to use the same cloning techniques on more fully developed cells. To be sure, not all
of the subsequent experiments yielded negative results. For instance, researchers were able to repeat the
31See Kolata, supra note 24, at 64.
32See id.
33See id. at 65
34Totipotent stem cells are deﬁned as:
Stem cells which are capable of forming every type of body cell. Each totipotent cell could replicate and diﬀerentiate and
become a human being. All cells within the early embryo are totipotent up until the 16 cell stage or so.
See General Term: Totipotent Stem Cells, at http://www.counterbalance.net/biogloss/totistem-body.html (last visited May
14, 2003).
7experiments on diﬀerent frog species,35 a result that lent support to the biological universality of the ability
to clone from blastula cells. Still, the researchers were not demonstrating the results in non-amphibians, and
so making broader generalizations proved to be a tenuous proposition at best. More importantly, the eﬀorts
to apply the methods to cells that were further along the developmental chain yielded sobering results. The
upshot of this body of ﬁndings was that, the further along in development of the organism from which the
genetic material was transferred, the less likely the chances of producing viable clones.
By the end of the 1960s, progress on the advancement of cloning technology in frogs had slowed down
considerably. It was generally conceded that the nucleii from diﬀerentiated frog embryo cells at an early
stage such as the blastula could be transferred to enucleated egg cell to produce viable organisms. These
organisms could advance to the tadpole stage, certainly, and probably develop further to the fully grown
adult frog.36 However, with respect to using nuclei from a fully grown adult frog, the furthest that cloning
experiments could get were organisms that developed to the tadpole stage.37 No one was able to produce
experimental results in which fully diﬀerentiated cell nucleii, taken from adult cells, could be used to general
fully grown frogs. At this point did the state of cloning advancement remain for the next few decades.
Understandably, regulation of the research was not stringent at this point, as it was conﬁned to frogs,
although the publication of a photograph of 30 cloned frogs in 1977 did cause a bit of a public stir.38
B. From Frogs to Mice
The science of cloning from adult cells did not witness any veriﬁable breakthroughs in the 1970s and 1980s.
35See Kolata, supra note 14, at 66
36See id. at 69.
37Id.
38See McLaren, supra note 20, at 1775.
8Save for a widely publicized claim in 1978 regarding human cloning, which later proved to be publicly
discredited in the legal system, and another more favorably received though ultimately discredited claim of
mouse cloning in 1981, cloning technology did not witness major substantive events in the aftermath of the
frog cloning experiments initiated by the work of Briggs and King.
The 1978 hoax was propagated by a science journalist who claimed that an anonymous millionaire had
approached him in an eﬀort to clone an heir for himself. David Rorvik, who had reported for such publications
as Time magazine and the New York Times, claimed that he had agreed to the rich man’s request and
proceeded to initiate a successful eﬀort to recruit the necessary personnel and create the desired clone.
Interestingly enough, events surrounding the 1978 announcement contain several parallels to the thus-far
unconﬁrmed claims of similar nature made by the present-day orchestrations of Claude Vorilhon and his eager
band of Raelian followers. Like the attention-hungry Vorilhon, Rorvik discovered that the cloning vehicle
could be used to travel on the fast track to public notoriety. Similarly to Vorilhon, Rorvik subsequently
discovered that the path also led to the type of infamy characterized by widespread and deserved mocking.
Along the way to this ignoble end, Rorvik, like Vorilhon’s cohorts at Clonaid, provided various excuses and
pretenses with respect to why substantive veriﬁcation of claims to human cloning could not be provided. As
in the past several months with Clonaid, Rorvik felt the sudden urge to protect the privacy of the putatively
cloned individual and other interested parties, despite having notiﬁed the international community of their
existence. In Rorvik’s case, this had taken the form of a work of “non-ﬁction” entitled “In His Image: The
Cloning of a Man.”39 Vorilhon was perhaps more guarded in the sense that the announcement took place
in the form of a press conference, yet the salient fact was that the announcement was made, and to an
international audience.
39David M. Rorvik (1978)
9Another similarity to present day events was the fact that Rorvik was met with skepticism by the scientiﬁc
community. Much like Vorilhon has recently been met with debunkers, naysayers followed closely in the wake
of the 1978 claim. In Rorvik’s case, however, the degree to which his attackers proceeded was untempered by
present-day advances in the state of cloning technology. These doubters attended a Congressional hearing
that Rorvik ﬁrst delayed and ultimately failed to make. Perhaps the general tenor of the attitude toward
Rorvik and his fantastical claims is most politely expressed by relating that the most favorable comment
made by one of the scientists was that Rorvik’s book was “mildly amusing.”40 All agreed, however, that his
was a work of science ﬁction, the imaginings of a strangely misguided professional who had, until that point,
managed to develop a solid reputation as a credible science journalist.
Vorilhon diﬀers from Rorvik in that the former’s background does not have a cach´ e that lends itself to a
presumption that reports of scientiﬁcally legitimate breakthroughs may actually be legitimate. Vorilhon
happened upon the subject of cloning following failed stints as a singer and as a publisher of an automobile
racing magazine.41 The foray into human cloning extended from the career move that transitioned Vorilhon
out of the relatively narrow roles of entertainer and publisher, and into the more generally-encompassing
position of cult leader. With such a scientiﬁcally inauspicious beginning, it perhaps comes as a surprise
that Vorilhon and his Raelian followers were not met with at least an equal degree of skepticism as that
encountered by Rorvik. Vorilhon, however, has beneﬁted from awareness of advances in cloning technology
that have made the public and scientiﬁc community more guarded, and justiﬁably so, in voicing vehement
doubt as to the probability of claims reporting the successful development of human clones from fully-
diﬀerentiated adult cells.
40See Kolata, supra note 14, at 103.
41See Rick Ross, The True Story of “little Claudy” Vorilhon, now known as “His Holiness Rael” (March 2003), at
http://www.rickross.com/reference/raelians/raelians77.html.
10The relevant developments in cloning technology have only been in the public consciousness for the past
ﬁve years. Biologically immediate precursors to these advances date back two decades, however. In early
1981, an announcement of cloned mice was made by the highly respected researcher Karl Illmensee. These
mice were supposedly cloned from embryo cells, and so did not have the full eﬀect of cloning from a fully
grown adult cell. However, the scientiﬁc community recognized this as a major breakthrough. Unfortunately,
despite many eﬀorts to repeat the experiments, no one was able to replicate the reported results. In addition,
suspicions arose within the scientiﬁc community as to the integrity of the experiments involved in the original
claims.42 As it turned out, some in the scientiﬁc community came to believe that the original reports of mouse
clones were at best suspect, and that Illmensee had not developed the requisite techniques for attempting
such experiments.
Following these events, other researchers did manage to advance the state of the technology insofar as intro-
ducing a mouse nucleus into a fertilized mouse egg was concerned. In the ﬁrst of this series of experiments,
the nucleus from a fertilized mouse egg was transferred to another fertilized mouse egg through the use of an
inactivated virus to fuse the introduced nucleus with the host egg cell. This experiment met with success,
producing viable oﬀspring mice. However, while the technique for manipulating mice nucleii and egg cells
had advanced, this did not represent progress on the front of mouse cloning, because diﬀerentiated cells
had not been used in these experiments. When the experiments shifted from using fertilized eggs as the
donor cells to using donor cells that were further along the developmental pathway, the results dramatically
shifted. No viable mice oﬀspring were produced, and the results were even considerably less promising than
the limited success of the frog experiments. Whereas the frog researchers were able to make tadpoles from
early embryonic cells, the mice researchers were unable to achieve more than a few cellular divisions using
42See Kolata, supra note 14, at 130-144.
11cell nuclei from the two-cell embryo stage, which, next to the fertilized egg, is the earliest stage of biological
development. The researchers subsequently reported the impossibility of creating mammalian clones in the
December 1984 issue of the prominent research periodical Science.43 For some time afterwards, the focus of
the research-oriented developmental and molecular biologists shifted away from cloning.44 The public eye,
already not overly-focused on what seemed to be a tangentially-relevant scientiﬁc endeavor, shifted even
further away from developments in mammalian cloning research.
C. From Sheep to Cows
The cloning of mammals using fully diﬀerentiated adult cells caught the larger scientiﬁc community by
surprise. In the aftermath of the unencouraging mouse experiments of the 1980s, scientists focused on
research had shifted away from the pursuit of clones and instead embraced other subjects such as the
characterization of the many genes involved in regulating cell growth and activity. Still, experimental work
on cloning did not cease. It simply became relegated to one of the less luminous circles of science, where
agricultural research funded by private interests reside. The two groups that pushed the boundaries of
cloning research were located on opposite sides of the Atlantic, one in Wisconsin and the other in England.
Of the Wisconsin group, Gina Kolata, a noted science correspondent for the New York Times, writes, “The
only true surprise was that its researchers were so amazingly successful in the face of enormous inexperience
with the new techniques needed for cloning.”45 This group, working with funding from W. R. Grace and
Company, was attempting to clone cows for the purpose of commercial applications, namely, to proﬁt from
43See id. at 146.
44See id. at 132.
45See id. at 159.
12the sale of cloned prize animals. The group succeeded in their attempts in the Fall of 1986, and published
their results in the subsequent year.46 Despite the prevalent report that mammalian clones were a biological
impossibility, this group successfully cloned cows using early-stage embryonic cells. In addition to the
practical problems in working with adult cows, the group was able to surmount such obstacles as to how to
fuse the donor nuclei with the host egg cell and how to keep the newly-created embryos viable until they
were ready for surgical transplantation into the surrogate mother cow. The latter problem was solved by
implanting the new cow embryos into sheep oviducts. To the ﬁrst question of method of fusion, the Wisconsin
team used an apparatus that gave oﬀ an electrical pulse to facilitate nucleus to egg cell fusion. This solution
proved to be quite signiﬁcant to the development of cloning technology, as the method was also later used
by Wilmut and Campbell to reinitiate the cell cycle of egg cells into which new nucleii had been injected.47
Working at the same time as the Wisconsin group on the problem of mammalian cloning was Steen Willadsen.
Willadsen came up with the innovation of using unfertilized host eggs instead of host eggs that had already
been fertilized prior to introduction of the new nucleus. This led to the birth, in 1984, of lambs that had
been created using this technique in conjunction with the same cell fusion technique used in the earlier mouse
experiments, the same experiments used for support of the declaration that cloning mammals was impossible.
Shortly thereafter, Willadsen happened upon using electrical pulses to fuse the introduced nucleus with the
host egg cell, similar to but independent of the same technique employed by the Wisconsin group. At roughly
the same time that the mainstream research scientists were abandoning cloning research, Willadsen and the
Wisconsin group, working in relative obscurity, were expanding the frontiers.
46See id. at 167.
47See text accompanying notes 48-52, infra.
13Willadsen and the Wisconsin group published their ﬁndings in 1986 and 1987, respectively. Although neither
of the two had employed diﬀerentiated cells taken from fully grown adults in the creation of their clones, their
results were signiﬁcant enough to displace the assertion that mammals could not be cloned. The Wisconsin
group continued to research ways in which cows could be cloned, and Willadsen began to work in the same
ﬁeld when he moved to the United States to work for a company interested in marketing clones of prize
cattle.
Despite the encouraging results, the scientiﬁc advance in the state of cloning knowledge subsequently slowed.
In a demonstration of how commercial interests can drive science, progress on cloning technology came to a
standstill when the monetary motive behind cloning cows proved not to be as lucrative as originally thought.
By the early 1990s, the original researchers involved in pushing the state of cloning science forward in the
previous decade had moved on to other projects. At this point, the state of the technology remained at the
point where it was possible to take early-stage embryo cell nucleii and make clones, but it was not possible
to do the same using cell nucleii from fully-grown adults.48
This all changed with the cloning eﬀorts of Ian Wilmut and Keith Campbell. In 1996, they reported work
in the journal Nature that they had successfully cloned sheep from cells that had, in a laboratory culture,
diﬀerentiated from early embryo cells.49 However, this announcement was met mostly with indiﬀerence
from the scientiﬁc community. For the people who did pay attention to the result, the reaction was more
akin to skepticism than optimism.50 Because the cells used by Wilmut and Campbell were derived directly
48Although anecdotal accounts suggest that cells from embryos as far along in the developmental stage as one week had been
successfully used to create clones, this research was never published.
See id. at 187.
49See Keith H. S. Campbell et al., Sheep Cloned by Nuclear Transfer from a Cultured Cell Line, 380 Nature 64 (1996).
50See Kolata, supra note 14, at 215.
14from early embryo cells, it was thought possible that the cloning had actually been performed using non-
diﬀerentiated genetic material, which was not an advance from earlier experiments. In fact, this result was
of enormous signiﬁcance, and it was in the following year that the pair announced results that cloning using
genetic material from a fully grown parent had been achieved.
The innovation employed by Wilmut and Campbell in successfully cloning an adult sheep was the same one
they used in the 1996 Nature article. However, what made the next experiment diﬀerent was that, instead
of using early embryo cells that had already diﬀerentiated, they used cells from udder cell tissue that had
been stored in deep-freeze conditions. This tissue came from a sheep that had already died three years
before Wilmut and Campbell attempted to make the clone.51 Thus, when Dolly was born in July 1996,52
her biological mother had long since passed away.
The announcement of Dolly’s birth caught the attention not only of the scientiﬁc community, but of the
international public. An adult mammal had been cloned, and it was time to consider the potential ramiﬁca-
tions, namely, the possibility that humans could also be genetically duplicated. The most timely questions
dealt with issues of feasibility and failure rates. The ensuing inquiries revealed that the cloning attempts
leading up to Dolly’s birth indicate that cloning, while technically possible, was by no means eﬃcient or safe.
Beginning with 277 udder cells, Wilmut and Campbell transferred the nucleii from those cells to egg cells.
Using their novel technique of starving the donor cells to the point where they entered the G0 (quiescent)
phase of the cell cycle,53 and then introducing a series of electric pulses to the newly-injected eggs to induce
further development, the scientists were able to obtain 29 embryos. They transferred these embryos to sur-
rogate mothers that were also sheep, but had noticeably diﬀerent physical characteristics than the original
sheep from whom the udder cells had been taken. Ultimately, only one lamb, the soon-to-be-famous Dolly,
was born.
51See id. at 216
52See id. at 219
53See Keith H. S. Campbell et al., Sheep Cloned by Nuclear Transfer from a Cultured Cell Line, 380 Nature 64 (1996).
15To reiterate the point concerning failure rates, it is not this single success that gives immediate pause re-
garding reproductive cloning. Even before considering the gravitic ethical issues associated with such a
practice, issues of safety and eﬃcacy warn against attempting to apply these techniques to humans. It is
the 276 failed Dolly’s that fueled and continue to feed the ﬁre of criticism based strictly upon the feasibility
of this reproductive technique. Of the hundreds of eggs used for the Dolly experiments, barely 10% of them
made it to the early embryo stage,54 and fewer still made it to one week, where development reaches the
blastula stage in sheep.55 Ultimately, there was only successful attempt from the creation of 29 embryos.
The eﬃcacy of this technique has not been demonstrated in humans, nor any kind of primate. However,
even if scientists successfully clone, for instance, a chimpanzee, it would, without a doubt, be unacceptable
to both proponents and opponents of human cloning to have a failure rate of 28 out of 29 embryos. This is
notwithstanding the fact that roughly ten times this amount of egg cells would be required to duplicate the
conditions of the original lamb cloning experiments. These egg cells, of course, would have to come from
human egg donors.
One counterstrain of thought to the belief that cloning is simply too dangerous to be practiced on humans
argues that, in some respects, cloning is actually safer than other forms of reproduction. Critics point to fail-
ure rates for early in vitro fertilization attempts and note that this technique, in its early stages, failed rather
frequently. Lee Silver, a prominent biologist, points out that the success rate for the Dolly experiments, is
far greater than the success rates of early human in vitro fertilization eﬀorts.56 Furthermore, cloning from
the cells of a grown adult sidesteps the most common cause of birth defects, which is an incorrect number of
chromosomes. During the creation of sex cells, sperm and eggs sometimes end up with too few or too many
54See Kolata, supra note 14, at 218. But see id. at 239 (“Some cloning critics have said that it is clear from the Dolly
experiment that cloning is unsafe because Ian Wilmut started out with 277 eggs and ended up with a single sheep. But, Silver
noted, only 13 of those eggs developed into embryos and 12 of the 13 were miscarried early in pregnancy.”)
55See ANS 431: Early Embryonic Development, at http://www.siu.edu/∼tw3a/431emb.htm (last visited May 14, 2003).
56See Lee Silver, Remaking Eden: Cloning and Beyond in a Brave New World (1998).
16chromosomes.57 Most of the time, if these sex cells are involved in fertilization, there will be a miscarriage.
However, those individuals who do survive to birth have such genetic irregularities as Down’s syndrome and
Tay-Sachs disease.58 Regardless of the merits of this argument, the fact that it and other human cloning-
related discussions were being entertained in the mainstream indicated that the public consciousness had
been raised. Serious discussions over policy was to follow, followed later still by substantive action in the
legislative and regulatory realms.
D. Of Mice and Humans?
Potentially diminished risks of genetic irregularities may cause some to point to reproductive cloning as a
safer alternative to traditional reproductive practices. Certainly, the safety disincentive has not completely
dampened enthusiasm for the technology. The high probability of a substantial failure rate for initial human
cloning attempts has not prevented all attempts to experiment with this technique. As discussed at the
outset of this paper, Clonaid, the brainchild of Claude Vorilhon, claims to have actually created viable
human clones. But Clonaid, despite being subject to a good deal of justiﬁed skepticism, has not been alone
in its putative eﬀorts to clone using adult human cells as the source of genetic material. Outside the thus-far
unveriﬁed claims of Clonaid, at least one entity has gone so far as to attempt to create human embryos using
human donor egg cells and genetic material from human adults.
In the United States, the only credible claim to human cloning attempts to date have involved a company
called Advanced Cell Technology. In the November 24, 2001 issue of Scientiﬁc American, members of this
company reported their results in an eﬀort entitled, “The First Human Cloned Embryo.”59 This piece
57See Kolata, supra note 14, at 238.
58See id. at 238-239.
59See Michael West et al., The First Human Cloned Embryo, Scientific American (Nov. 24, 2001), available at
http://www.sciam.com/print version.cfm?articleID=0008B8F9-AC62-1C75-9B81809EC588EF21 (last visited May 14, 2003).
17reports the group’s eﬀorts throughout the entire process, from recruiting egg donors to culturing one of
the embryos to the six-cell stage. The group reportedly undertook the ﬁrst cloning attempt in July 200160
After injecting 71 eggs with genetic material from diﬀerentiated adult cells, the members of Advanced Cell
Technology succeeded in inducing three of those cells to divide. None of these three embryos divided past
the early embryonic stages, with the most advanced one reaching the six-cell stage.
The success of Advanced Cell Technology’s attempts were founded upon earlier work on mouse cloning
done at the University of Hawaii. In 1998, two years after the birth of Dolly, Teruhiko Wakayama and his
laboratory successfully cloned mice using a novel source for the injected cell nucleus. Instead of using cells
from skin tissue, Wakayama and cohorts used cumulus cells, adult cells which surround the egg. Cumulus
cells have all of the genetic material of other diﬀerentiated adult cells, but they tend to be considerably
smaller than the average adult cell. For this reason, it was possible for these cells to be injected into the eggs
whole, without undertaking the extra step of removing the nucleus. According to the Scientiﬁc American
article, Wakayama was aﬃliated to Advanced Cell Technology after the successful mouse cloning trials at
the University of Hawaii.61 When the human cloning attempts were performed, some egg cells were injected
with ﬁbroblast (skin cell) nuclei, and other egg cells were injected with whole cumulus cells. All three of the
embryos that the company created used the cumulus cell injection method.
In another set of experiments, the members of Advanced Cell Technology utilized a technique known as
parthenogenesis to make embryos. Parthenogenesis makes use of the genetic material found in an egg cell.
Until late in the maturation cycle, the egg cell possesses the same amount of genetic material as a normal cell
found elsewhere in the body. However, an immature egg cell with the full complement of genetic material,
under normal conditions, cannot divide in the same manner an embryo does to result eventually in an
organism. By chemically altering the environment surrounding an unfertilized egg, West and his group
60See id.
61See id.
18successfully induced parthenogenesis, causing the egg cell to undergo changes that resulted in division into
an embryo. Six of these egg cells developed to the blastula stage, considerably further than the six-cell stage
of the most advanced cloned embryo. Although parthenogenesis makes use of the genetic material found in
the egg, it is not cloning. The genetic material resulting from parthenogenesis, although very similar to that
found in an adult somatic cell with a full complement of DNA, is not identical to it. The reason is that,
during formation of sex cells, the genetic material in a person’s body is mixed up in a process known as gene
shuﬄing. Whereas a normal body cell contains the genetic material prior to shuﬄing, a parthenogenetically
activated cell contains DNA that has been reordered.62
The rationale for performing parthenogenesis experiments speaks to a fundamental diﬀerence between the
aims of Advanced Cell Technology and the interests represented by Clonaid. The former seek to utilize the
capabilities of cloning technology for medically therapeutic purposes, whereas the latter wish to make genetic
replicas of people. Although it would be ideal for medical purposes to have identically matching tissue on
the genetic level, highly similar genetic material will also serve a therapeutic end. For example, a patient
who requires an organ transplant may have a narrow chance of ﬁnding a matching donor, but if technology
can be used to produce organs from parthenogenetically activated cells, then the chances of producing tissue
that will not be rejected by the body’s immune system might increase considerably. But for those seeking
to pursue reproductive cloning, a close genetic match might not suﬃce. West and the others at Advanced
Cell Technology, by taking parthenogenetically activated tissue to the blastula stage, brought the state of
technology that much closer to the point where embryonic stem (ES) cells can be obtained from a person’s
own cells.
62See id.
19E. Embryonic Stem Cells
So what are the advantages to researchers at the present moment of using ES cells? To gain a full appreciation
of the beneﬁts, it is useful to understand the distinction between ES cells and other cells found during
embryonic development. When an egg is fertilized, the cell that results is a zygote, the ﬁrst cell of the
embryo. At this point, that single cell is totipotent. In other words, the cell can (and does) develop into any
other type of cell in the adult body. When the cell divides, it becomes two cells attached to each other. At
this point, both of these cells are still totipotent. In fact, the cells undergo several more divisions until they
become a solid mass of cells attached to each other. This mass of cells is known as a morula, from the Latin
morum, which means blackberry. One can imagine a morula as being similar to a microscopic blackberry,
with the cells on the outside forming the little bumps that gives the fruit its surface texture.
The cells of the morula are also totipotent. Potentially, every one of these cells can develop into any type of
tissue. However, in the next stage, the morula begins to fold inward and the cells, which are still dividing,
begin to diﬀerentiate, or divide into cells that are no longer totipotent. One can imagine this process by
thinking of the making of a pot from a round ball of clay. This structure becomes closed oﬀ, in a manner
akin to extending the sides of the pot such that they close oﬀ the center opening. At this point, the embryo
is called a blastula, and can be appropriately described as a hollow mass of cells. It is from within the
blastula that embryonic stem cells are found. However, at this point, the cells of the embryo are no longer
totipotent. Rather, they are pluripotent, unable to divide into every type of tissue found in the adult.
Still, the pluripotent ES cells retain the capacity to become most other types of adult tissue. The types of
cells that ES cells cannot become are trophoblasts, which eventually form the fetal portion of the placenta,
the biological structure through which nutrients are exchanged between the mother and child. Other than
the trophoblasts, it is thought that ES cells can develop into all of the other types of adult tissues. This
20ability to divide into all other types of cells and tissues is what makes ES cells so critically important to
future scientiﬁc developments. From a strictly medical standpoint, research in ES cells could ultimately lead
to the day where a paralysis victim could be given a new spinal cord or someone who had experienced a
massive heart failure could be given a new heart. What distinguishes these applications from present similar
endeavors, however, is that if doctors use ES cells created from a patient’s own cells, the immunochemical
rejection associated with current transplants would not be an issue.
Given the above description of the developmental process, one natural question to ask is why ES cells, as
opposed to cells that are found earlier in development, must be used for research purposes. The answer is
that scientists do not know how to culture the earlier totipotent cells, whereas the knowledge to maintain
ES cells in a laboratory environment does exist. For mice, scientists have long been maintaining ES cell lines
and using these cells to investigate the function of various mouse genes.63 The advantage of having many
ES cells available in petri dish cultures is that the genetic material of some of these cells can be altered.
However, the process by which the genetic is altered requires a very large of amount of cells, because only a
very small proportion of the cells are successfully altered. Once researchers identify the cells that have been
successfully changed, these cells can be reintroduced into the biological context by combining them with cells
of a diﬀerent developing mouse embryo. What happens afterwards is that the adult mouse has some cells
that are from its original parents, and some cells that are from the altered ES cells. The hope is that some
of the ES cells are present in the gametes, or sex cells, so that when these mice are mated with other mice,
some of the oﬀspring will have the altered genetic material in all of their cells. The mice with fully altered
genetic material can then be used for further studies.
Embryonic stem cell technology has the potential to treat many diseases and medical needs. The ability of
these cells to grow into most any type of tissue found in the adult body presents the opportunity to grow
63See Kolata, supra note 14, at 197.
21cardiac muscle for heart problems and neural cells for such conditions as Alzheimer’s and Parkinson’s.64
Given the shortage of organs available for transplant,65 the potential to use ES cells to grow into any type of
tissue may solve a longstanding medical quandary. As with any type of tissue transplant, organs derived from
ES cells run the risk of being rejected by the recipient. If the ES cells are derived using nuclear transfer,
with the nucleus originating from one of the organ recipient’s cells, then the problem of incompatibility
disappears.
One of the ethical dilemmas in pursuing this course of treatment is that, currently, the derivation of ES
cells requires the creation of an embryo, and development of that embryo to the one-week old stage. In the
process of cultivating the ES cells, the embryo is destroyed. Some ﬁnd this to be an intolerable violation
and termination of life. Another moral problem is that such medical technology, were it available, using ES
cells derived from the patient’s genetic material, could be used to create genetic clones of people. The next
section examines regulatory eﬀorts to prevent this eventuality.
III. Eﬀorts to Prevent and Sanction Human Cloning
To this point, there has been no broad ban passed on human cloning on the federal level.66 There has been
a limited ban placed upon experimentation with cloning or embryonic stem cells.67 With respect to most
research, the control mechanism has been through regulation of federal funds. Congress placed a ban on NIH-
64See Anne McLaren, Stem Cells: Golden Opportunities With Ethical Baggage, 288 Science 1778 (2000).
65See Jennifer Ryan and Dorsey Edwards, Can a Website Solve the Organ Shortage Crisis in America?, WUSA 9 – Health,
Feb. 26, 2003, at http://www.wusatv9.com/health/health article.asp?storyid=15133 (last visited May 14, 2003) (stating that
“[s]eventeen Americans die every day waiting for an organ transplant”).
66See AAAS Policy Brief: Human Cloning, American Association for the Advancement of Science, available at
http://www.aaas.org/spp/cstc/issues/cloning.htm (updated Jan. 2003) (last visited May 14, 2003).
67See AAAS Policy Brief: Stem Cell Research, American Association for the Advancement of Science, available at
http://www.aaas.org/spp/cstc/issues/stemcells.htm (updated Aug. 14, 2002) (last visited May 14, 2003).
22funded human embryo research in 1995, and that ban has been in eﬀect in each year’s appropriations bill ever
since.68 However, this mechanism does not speak to private individuals and corporations such as Clonaid
and Advanced Cell Technology. The regulatory structure here remains murky and awaits further clariﬁcation
via Congressional legislation or Executive order, but the FDA appears to be the existing regulatory agency
with suﬃcient resources and recognition to address private eﬀorts.69 It is conceded that the FDA possesses
oversight authority of tissues used for transplant,70 from which may arise regulatory authority over human
cloning attempts.
On a practical level, the FDA has been largely successful in preventing or discouraging human cloning
attempts in the United States. Clonaid is no stranger to regulatory eﬀorts by the FDA. The company website
acknowledges that, in 2001, representatives from the government made “several visits” to the company’s
facilities.71 Following these visits, the company decided to relocated to “another country where human
cloning is legal.”72 According to Bernard Stone, a spokesman for the Agency, in 2002 the FDA investigated
and shut down a Clonaid laboratory in Nitro, West Virginia.73 After the December 2002 announcement, the
FDA had began another investigation into the organization.74
At the same time, not all attempts in the United States to apply cloning technology to humans have been
prevented. As seen in the previous section, the FDA did not stop Advanced Cell Technology from undertaking
a series of attempts to create a human embryo using cloning technology.75 However, actions taken subsequent
to the reporting of these experiments may have deterred further attempts, at least for the time being. During
68See id.
69See, e.g., Regulating Human Cloning, American Association for the Advancement of Science, Apr. 3, 2003, available at
http://www.aaas.org/spp/cstc/issues/cloningreport.pdf (last visited May 14, 2003).
70Id. at 7.
71See The First Human Cloning Company, A Historical Background, at http://www.clonaid.com/english/pages/history.html
(last visited May 14, 2003).
72Id.
73See Linda Greenhouse, F.D.A. Exploring Human Cloning Claim, The New York Times, Dec. 30, 2002, at A10.
74See id.
75See II.D, supra.
23a January 2003 panel on human cloning, CEO Michael West described the attempts of FDA regulators to
inspect and shut down the company’s facilities.76 In the aftermath of these inspections, Advanced Cell
Technology has not reported further attempts to extend their previous line of research involving human
cloning and embryonic stem cells.
General public sentiment against such attempts provide another source of regulation. This has manifested
itself in litigation brought on behalf of cloned individuals, despite the unconﬁrmed existence of these children.
Bernard Siegel ﬁled a suit against Clonaid in Florida court, claiming that Eve is an abused child.77 The
rationale behind this suit was that cloning technology is too unreliable and stands too great of a chance for
birth defects to ensure the birth of healthy children. Hence, to subject an individual to this high possibility
of death or defect is tantamount to abuse.
For the time being, these oﬃcial and private regulatory eﬀorts may be enough to prevent further human
cloning attempts in the United States. Based upon current scientiﬁc understandings and social conventions,
it is necessary that an eﬀective ban on human cloning be made at this point. Such cloning attempts are
highly unlikely to succeed, and any measure of success will be accompanied by many more highly undesirable
outcomes. And if technology ever exists to carry out the process of taking a nucleus from an adult human’s
diﬀerentiated cell, creating an embryo, harvesting the ES cells, and coaxing these cells to grow into tissues
to be used for medical therapy of the same person, moral qualms will still plague application. Until such
time that science reaches the point where ES cells can be derived without going through the intermediate
step of creating embryos, or social attitudes toward creating embryos strictly for medical purposes change,
it unlikely that this technology will be widely accepted in the United States.
76See Human Cloning Panel, Harv. J. Law & Tech., Jan. 21, 2003, available at http://media.law.harvard.edu:8888/
ramgen/jolt/spring 03/2003-01-22 h102 0630-0730.rm (last visited May 14, 2003).
77See Russ Mitchell, CBS Early Show interview with Bernard Siegel, Jan. 2, 2003.
24IV. Conclusion
When news of the ﬁrst successful cloning of a mammal using the genetic material of an adult sheep reached the
public, the policy-making and -eﬀecting mechanisms were too late to stop the advent of this technology. In
the six years since this ﬁrst successful cloning attempt, the state of knowledge has advanced yet further, and
techniques have improved. The technical problems more speciﬁc to cloning humans have become clearer,
in the form of cloning research on other primates.78 As is the wont of researchers, these problems have
been met with proposed solutions.79 Advances in knowledge of basic cellular mechanisms, though broader-
ranging in application than cloning, also contribute to our ability to make genetic duplicates of any organism.
Doubtlessly, research will continue and may well eventually reach the point where human cloning is possible.
This eventuality should not lead us to condemn the original discoveries, for advances in knowledge and
technology are not, in and of themselves, deleterious. While retrospection is oftentimes described as clear-
sighted, the problem with looking back in the scientiﬁc and technological contexts is that policy regulates
application of principles rather than the direction of discovery. Oftentimes, no one even anticipates a
particular manner in which a new discovery can be applied. Asking policymakers and regulators to prevent
all future innovations that may have potentially negative applications is basically asking them to make time
stand still. The only way to prevent any conceivably harmful eventuality would be to have everyone sit on
their hands and do nothing. Instead of focusing our eﬀorts on soothsaying and its attendant frustrations,
we should concentrate on ensuring that existing technology is harnessed in a beneﬁcial manner.
For human cloning, this means that regulators must act to prevent all possible attempts at this time.
While the technology exists to perform the procedure, our current understanding of cell programming and
78See Calvin Simerly et al., Molecular Correlates of Primate Nuclear Transfer Failures, 300 Science 297 (2003).
79See id.
25development is not suﬃcient to ensure success, much less safety. There are also threshold questions that
need to be resolved, questions that implicate our conceptions of sentience and life. Now that technology has
opened the door, regulation must earnestly work to ensure that our application of these profound discoveries
does not create a Pandora’s Box of ethical and biological catastrophes.
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